Loading...
OTCM
HSTOQ
Market cap4kUSD
Jun 10, Last price  
0.00USD
1D
-8.33%
Jan 2017
-100.00%
IPO
-100.00%
Name

Histogen Inc

Chart & Performance

D1W1MN
P/E
—
P/S
0.00
EPS
—
Div Yield, %
—
Shrs. gr., 5y
2.35%
Rev. gr., 5y
-36.10%
Revenues
4m
+310.12%
000799,04635,376,79633,586,00011,304,0002,059,000919,0003,769,000
Net income
-10m
L-27.24%
-15,616,492-22,319,891-24,148,626-29,733,441-17,396,413-18,010,000-4,898,000-25,774,000-14,405,000-10,481,000
CFO
-10m
L-33.37%
-10,631,717-18,260,155-22,546,19026,997,001-33,210,040-34,975,000-1,291,000-12,054,000-14,532,000-9,683,000

Profile

Histogen Inc., a clinical-stage therapeutics company, focuses on developing proprietary hypoxia-generated growth factor technology platform and stem cell-free biologic products. It offers HST-003, a human extracellular matrix, which is in Phase 1/2 clinical trial to treat articular cartilage defects in the knee; HST-004, a cell conditioned media solution to treat spinal disc repair; and Emricasan, an orally active pan-caspase inhibitor for the treatment of COVID-19. The company's preclinical product candidates include CTS-2090 and CTS-2096, which are selective caspase-1 inhibitors targeting inflammasome activation, as well as intervenes in a various inflammation mediated disease. Histogen Inc. was founded in 2007 and is headquartered in San Diego, California.
URL
https://histogen.com/
IPO date
Jul 25, 2013
Employees
7
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFY
2022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
3,769
310.12%
Cost of revenue
14,552
Unusual Expense (Income)
NOPBT
(10,783)
NOPBT Margin
Operating Taxes
(163)
Tax Rate
NOPAT
(10,620)
Net income
(10,481)
-27.24%
Dividends
(488)
Dividend yield
18.31%
Proceeds from repurchase of equity
3,917
BB yield
-146.97%
Debt
Debt current
238
Long-term debt
9,006
Deferred revenue
79
Other long-term liabilities
Net debt
(2,865)
Cash flow
Cash from operating activities
(9,683)
CAPEX
(216)
Cash from investing activities
(216)
Cash from financing activities
3,323
FCF
(10,513)
Balance
Cash
12,109
Long term investments
Excess cash
11,921
Stockholders' equity
(89,297)
Invested Capital
107,212
ROIC
ROCE
EV
Common stock shares outstanding
3,211
Price
0.83
-87.53%
Market cap
2,665
-79.12%
EV
(1,229)
EBITDA
(10,643)
EV/EBITDA
0.12
Interest
1,000
Interest/NOPBT